Physician profile
Sunil Sharma
NPI 1265409676
$17,200.89
in general payments reported to CMS, 2019-2025
8 companies · $3,232 in 2025
The $3,232 reported for 2025 was more than what 84% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.68 · 2021: $7.50 · 2022: $6,284 · 2023: $3,022 · 2024: $4,644 · 2025: $3,232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $9,000 · Food and Beverage: $1,055 · Travel and Lodging: $764 · Education: $78.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $9,000.00 |
| Food and Beverage | $1,054.95 |
| Travel and Lodging | $764.02 |
| Education | $78.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $10,451.48 | 2023-2025 | Remede System |
| Actelion Pharmaceuticals US, INC. | $6,190.28 | 2022-2024 | Uptravi, Opsumit |
| United Therapeutics Corporation | $201.67 | 2021-2022 | |
| Boston Scientific Corporation | $144.15 | 2024 | Avvigo Guidance System |
| Regeneron Healthcare Solutions, INC. | $112.27 | 2024 | Dupixent |
| Pfizer INC. | $89.36 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $11.68 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sunil Sharma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.